MedTrace Logo

Effect of Domperidone on QT Interval in Premature Infants

NCT00238056 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2015-01-27

No results posted yet for this study

Summary

30 premature infants treated by domperidone upon decision of the attending neonatologist will have a daily recording of electrocardiogram for the first 7 seven days of treatment, and pharmacokinetics dosages at Day 7. Their ECG will be compared to 30 non treated premature infants, matched for gestational age, postnatal age and sex.

Conditions

  • Prematurity and Feeding Intolerance

Interventions

DRUG

domperidone Drug

Sponsors & Collaborators

  • Nantes University Hospital

    lead OTHER

Principal Investigators

  • Véronique Gournay, MD · Service de Cardiologie et Service de Réanimation Néonatale CHU de Nantes

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
10 Days
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00238056 on ClinicalTrials.gov